25 may 2012
Research Group from the USA Becomes Winner of RUSNANOPRIZE 2013
The RUSNANOPRIZE International Nanotechnology Prize Committee named the winners of the 2013 prize, which is awarded in the field of nanomaterials and surface modification. The prize goes to Massachusetts Institute of Technology Institute Professor Robert Langer and Harvard Medical School Professor Omid Farokhzad for the development and industrialization of nanoparticle technologies for medical applications.
Prof. Langer and Prof. Farokhzad have created combined nanoparticles, the surfaces of which are covered with biological ligands, i.e. molecules that recognize specific targets in the body, for example, the surface of cancer cells. The interior of the nanoparticles is composed of biologically inert polymer which binds the active substance, for example docetaxel, which is traditionally used in chemotherapy. These particles may circulate for a long time and be retained in the blood, and so they accumulate only around the tumor cells. Based on this technology, in particular, drugs have been created for the treatment of brain tumors, which are difficult to treat with traditional methods.
The winning research is a junction between biotechnology and material science. Prof. Langer’s research has laid foundation for new developments in the field of biomaterials as well as for applying nanomaterials in medicine and biology. Aside from his research in bio-compatible polymers for drug delivery systems with controlled release and synthetic polymers for tissue engineering, Prof. Langer has pioneered creating many other new types of biomaterials, like shape-memory polymers and materials with controlled surface properties.
RUSNANOPRIZE 2013 award is also given to US-based BIND Therapeutics Inc. for the successful commercial application of Prof. Langer’s and Prof. Farokhzad’s research, developing Accurins™—a new class of highly selective targeted and programmable therapeutics.
The RUSNANOPRIZE 2013 award ceremony will be held on November 1 in Moscow as part of the Open Innovations Forum.